Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/15/2024 | Q1 2024 | -$2.80 | $0 | 04/01/2024 | Q4 2023 | -$12.67 | $0 | 09/28/2023 | Q3 2023 | -$8.19 | $0 | 11/02/2023 | Q2 2023 | $1.27 | $0 | 03/29/2023 | Q1 2023 | $1.23 | $0 | 05/01/2023 | Q4 2022 | -$26.84 | $0 | 09/28/2022 | Q3 2022 | -$24.80 | $0 | 05/13/2022 | Q4 2021 | -$139.00 | $494,665 | 09/30/2021 | Q3 2021 | -$485.36 | $494,664 | 12/31/2020 | Q4 2020 | -$67.90 | $494,665 |
---|
A. The conference call for TC Biopharm (Holdings) Plc's latest earnings report can be listened to online.
A. The conference call transcript for TC Biopharm (Holdings) Plc's latest earnings report can be read online.
A. TC Biopharm (Holdings) Plc (NASDAQ:TCBPW) has a recorded net income of $0. TC Biopharm (Holdings) Plc has generated $-24.38 earnings per share over the last four quarters.
A. TC Biopharm (Holdings) Plc (NASDAQ:TCBPW) has a price-to-earnings ratio of 0.42 and price/earnings-to-growth ratio is 0.01.